Can Humana Beat Q2 Earnings Estimates on Growing Premiums?

HUM enters Q2 earnings with strong premium and membership growth expectations, but rising medical costs and expenses could test its bottom line.

Zacks Investment Research • Jul 24, 2026

Kaskela Law Firm Announces Investigation of Humana Inc. (HUM) and Encourages Long-Term HUM Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Humana Inc. (NYSE: HUM) (“Humana”) on behalf of the company's long-term investors. Click here for additional information: https://kaskelalaw.com/case/humana/ Recently a federal securities fraud complaint was filed against Humana on behalf of certain investors who purchased shares of the company's stock between July 27, 2022 and October 1, 2024 (the “Wrongdoing Period”). According to the compla.

Business Wire • Jul 23, 2026

Humana (HUM) Expected to Beat Earnings Estimates: Should You Buy?

Humana (HUM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 22, 2026

Nomura Core Equity Fund Q2 2026 Portfolio Review

Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions. On balance, the Fund's artificial intelligence positioning was a net positive contributor to relative performance during the quarter. We added the Humana position on the view that earnings are at a cyclical trough, with MA margins currently depressed, in some cases negative, as elevated medical cost trends have outpaced premium growth across the industry.

Seeking Alpha • Jul 22, 2026

Humana (HUM) is a Great Momentum Stock: Should You Buy?

Does Humana (HUM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research • Jul 21, 2026

Is Humana (HUM) Stock Outpacing Its Medical Peers This Year?

Here is how Humana (HUM) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year.

Zacks Investment Research • Jul 17, 2026

Can Humana (HUM) Run Higher on Rising Earnings Estimates?

Humana (HUM) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research • Jul 16, 2026

UnitedHealth Earnings Crush Estimates and Give These Stocks a Boost

The healthcare giant posts better-than-expected second-quarter earnings and hikes its full-year guidance.

Barrons • Jul 16, 2026

Medicare's $50 Weight-Loss Drug Window Opens In July: What Smart Enrollees Do Before 2027

A weight-loss prescription that runs $149 to $449 a month at the pharmacy counter now costs some Medicare enrollees $50. Across a year, that is the difference between roughly $600 and more than $4,000, and whether you capture the savings depends on a coverage question most people do not realize they are answering.

Benzinga • Jul 16, 2026

Humana Eyes 3% Medicare Advantage Margin: Can It Deliver?

Humana targets a 3% Medicare Advantage margin by 2028 while pursuing 25% 2026 membership growth and rebuilding profitability despite industry headwinds.

Zacks Investment Research • Jul 13, 2026